Ribosomal S6 kinase 2 inhibition by a potent C-terminal repressor domain is relieved by mitogen-activated protein-extracellular signal-regulated kinase kinase-regulated phosphorylation - PubMed (original) (raw)
. 2001 Mar 16;276(11):7892-8.
doi: 10.1074/jbc.M009972200. Epub 2000 Dec 6.
Affiliations
- PMID: 11108720
- DOI: 10.1074/jbc.M009972200
Free article
Ribosomal S6 kinase 2 inhibition by a potent C-terminal repressor domain is relieved by mitogen-activated protein-extracellular signal-regulated kinase kinase-regulated phosphorylation
K A Martin et al. J Biol Chem. 2001.
Free article
Abstract
Ribosomal S6 kinase 2 (S6K2) is a recently identified serine/threonine protein kinase that phosphorylates the 40 S ribosomal protein S6 in vitro. S6K2 is highly homologous to S6K1 in the core kinase and linker regulatory domains but differs from S6K1 in the N- and C-terminal regions and is differently localized primarily to the nucleus because of a C-terminal nuclear localization signal unique to S6K2. We have recently demonstrated that S6K2 is regulated similarly to S6K1 by the mammalian target of rapamycin pathway and by multiple PI3-K pathway effectors in vivo. However, deletion of the C-terminal domain of S6K2 enhances kinase activity, whereas analogous deletion of S6K1 is inhibitory. Here, we characterize the S6K2 C-terminal motifs that confer this differential regulation. We demonstrate that the inhibitory effects of the S6K2 C-terminal domain are only partly attributable to the nuclear localization signal but that three C-terminal proline-directed potential mitogen-activated protein kinase phosphorylation sites are critical mediators of this inhibitory effect. Site-specific mutation of these sites to alanine completely desensitizes S6K2 to activating inputs, whereas mutation to aspartic acid to mimic phosphorylation results in an activated enzyme which is hypersensitive to activating inputs. Pretreatment of cells with the mitogen-activated protein-extracellular signal-regulated kinase kinase (MEK) inhibitor U0126 inhibited S6K2 activation to a greater extent than S6K1. Furthermore, S6K2 mutants with C-terminal deletion or acidic phosphorylation site mutations displayed greatly reduced U0126 sensitivity. Thus, MEK-dependent inputs to C-terminal phosphorylation sites appear to be essential for relief of S6K2 inhibition but less critical for activation of S6K1. These data suggest a mechanism by which weak PI3-K agonists can regulate S6 phosphorylation and selective translation in the presence of mitogen-activated protein kinase signaling.
Similar articles
- Mutational analysis of ribosomal S6 kinase 2 shows differential regulation of its kinase activity from that of ribosomal S6 kinase 1.
Phin S, Kupferwasser D, Lam J, Lee-Fruman KK. Phin S, et al. Biochem J. 2003 Jul 15;373(Pt 2):583-91. doi: 10.1042/BJ20021794. Biochem J. 2003. PMID: 12713446 Free PMC article. - Regulation of ribosomal S6 kinase 2 by effectors of the phosphoinositide 3-kinase pathway.
Martin KA, Schalm SS, Richardson C, Romanelli A, Keon KL, Blenis J. Martin KA, et al. J Biol Chem. 2001 Mar 16;276(11):7884-91. doi: 10.1074/jbc.M006969200. Epub 2000 Dec 6. J Biol Chem. 2001. PMID: 11108711 - Cross-talk between the ERK and p70 S6 kinase (S6K) signaling pathways. MEK-dependent activation of S6K2 in cardiomyocytes.
Wang L, Gout I, Proud CG. Wang L, et al. J Biol Chem. 2001 Aug 31;276(35):32670-7. doi: 10.1074/jbc.M102776200. Epub 2001 Jun 28. J Biol Chem. 2001. PMID: 11431469 - Ribosomal S6 kinase signaling and the control of translation.
Dufner A, Thomas G. Dufner A, et al. Exp Cell Res. 1999 Nov 25;253(1):100-9. doi: 10.1006/excr.1999.4683. Exp Cell Res. 1999. PMID: 10579915 Review. - Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks.
Magnuson B, Ekim B, Fingar DC. Magnuson B, et al. Biochem J. 2012 Jan 1;441(1):1-21. doi: 10.1042/BJ20110892. Biochem J. 2012. PMID: 22168436 Review.
Cited by
- Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer.
Sridharan S, Basu A. Sridharan S, et al. Int J Mol Sci. 2020 Feb 11;21(4):1199. doi: 10.3390/ijms21041199. Int J Mol Sci. 2020. PMID: 32054043 Free PMC article. Review. - Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.
Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, Fini M, McCubrey JA. Martelli AM, et al. Oncotarget. 2012 Apr;3(4):371-94. doi: 10.18632/oncotarget.477. Oncotarget. 2012. PMID: 22564882 Free PMC article. Review. - Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase.
Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG. Wang X, et al. EMBO J. 2001 Aug 15;20(16):4370-9. doi: 10.1093/emboj/20.16.4370. EMBO J. 2001. PMID: 11500364 Free PMC article. - Protein kinase C phosphorylates ribosomal protein S6 kinase betaII and regulates its subcellular localization.
Valovka T, Verdier F, Cramer R, Zhyvoloup A, Fenton T, Rebholz H, Wang ML, Gzhegotsky M, Lutsyk A, Matsuka G, Filonenko V, Wang L, Proud CG, Parker PJ, Gout IT. Valovka T, et al. Mol Cell Biol. 2003 Feb;23(3):852-63. doi: 10.1128/MCB.23.3.852-863.2003. Mol Cell Biol. 2003. PMID: 12529391 Free PMC article. - Mutational analysis of ribosomal S6 kinase 2 shows differential regulation of its kinase activity from that of ribosomal S6 kinase 1.
Phin S, Kupferwasser D, Lam J, Lee-Fruman KK. Phin S, et al. Biochem J. 2003 Jul 15;373(Pt 2):583-91. doi: 10.1042/BJ20021794. Biochem J. 2003. PMID: 12713446 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases